TY - JOUR
T1 - The EPO Fable in Professional Cycling: Facts, Fallacies and Fabrications
AU - Lodewijkx, HFM
N1 - exported from refbase (http://publicaties.ou.nl/show.php?record=1325), last updated on Tue, 31 Mar 2015 13:19:13 +0200
PY - 2014/7/10
Y1 - 2014/7/10
N2 - The massive doping schemes that surfaced in professional cycling suggest that riders’ performances, realized in
the controversial ‘epo era’ (>1990), are a cut above achievements delivered by their forerunners. We examined this
superior performances assumption (SPA) by conducting six historic studies, which all scrutinized archival records
of winning riders’ stage race and time trial performances demonstrated in the three European Grand Tours (Tour de
France, Giro d’Italia, and Vuelta a España; 1903–2013), including Lance Armstrong’s wins. Findings revealed that all
riders’ wins in the epo years are no exception to the variability in speed progress observed in the three races over
time and none of their achievements proved to be outliers. This also holds true for Armstrong’s performances. These
findings agree with results of a meta–analysis of epo studies we conducted, indicating that the ergogenic effects of
epo and blood doping on riders’ aerobic performances and associated cycling speeds are overrated. In conclusion, we
argue that our observations render the SPA doubtful. They also made us realize that arguments used in contemporary
discussions about effects of doping in cycling often involve psychological biases, false reasoning and fabrications.
They are presented in the closing sections of this contribution.
AB - The massive doping schemes that surfaced in professional cycling suggest that riders’ performances, realized in
the controversial ‘epo era’ (>1990), are a cut above achievements delivered by their forerunners. We examined this
superior performances assumption (SPA) by conducting six historic studies, which all scrutinized archival records
of winning riders’ stage race and time trial performances demonstrated in the three European Grand Tours (Tour de
France, Giro d’Italia, and Vuelta a España; 1903–2013), including Lance Armstrong’s wins. Findings revealed that all
riders’ wins in the epo years are no exception to the variability in speed progress observed in the three races over
time and none of their achievements proved to be outliers. This also holds true for Armstrong’s performances. These
findings agree with results of a meta–analysis of epo studies we conducted, indicating that the ergogenic effects of
epo and blood doping on riders’ aerobic performances and associated cycling speeds are overrated. In conclusion, we
argue that our observations render the SPA doubtful. They also made us realize that arguments used in contemporary
discussions about effects of doping in cycling often involve psychological biases, false reasoning and fabrications.
They are presented in the closing sections of this contribution.
U2 - 10.4172/2161-0673.1000141
DO - 10.4172/2161-0673.1000141
M3 - Article
VL - 4
JO - Journal of Sports Medicine and Doping studies
JF - Journal of Sports Medicine and Doping studies
IS - 3
M1 - 1000141
ER -